Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study

Diabetes Res Clin Pract. 2011 Jul;93(1):e25-8. doi: 10.1016/j.diabres.2011.03.009. Epub 2011 Mar 26.

Abstract

A randomized, crossover study compared the effects of atorvastatin, gemfibrozil and their combination on inflammatory markers in type 2 diabetes. C-reactive protein (CRP), lipoprotein-associated phospholipase A2 (Lp-PLA2), secretory phospholipase A2 (sPLA2), interleukin 8 (IL8), monocyte chemotactic protein 1 (MCP1) and tumor necrosis factor α (TNFα) were measured. Both lipid-lowering drugs had positive, complementary and additive effects on inflammatory markers, which were closely related to baseline inflammatory status.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Alkyl-2-acetylglycerophosphocholine Esterase / blood
  • Aged
  • Atorvastatin
  • C-Reactive Protein
  • Cross-Over Studies
  • Diabetes Mellitus, Type 2 / blood*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Female
  • Fibric Acids / therapeutic use*
  • Heptanoic Acids / therapeutic use
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Inflammation / blood*
  • Inflammation / drug therapy*
  • Male
  • Middle Aged
  • Phospholipases A2 / blood
  • Phospholipases A2, Secretory / blood
  • Pyrroles / therapeutic use

Substances

  • Fibric Acids
  • Heptanoic Acids
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Pyrroles
  • C-Reactive Protein
  • Atorvastatin
  • Phospholipases A2
  • Phospholipases A2, Secretory
  • 1-Alkyl-2-acetylglycerophosphocholine Esterase